# A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

> **NCT01810939** · PHASE3 · COMPLETED · sponsor: **Relypsa, Inc.** · enrollment: 243 (actual)

## Conditions studied

- Chronic Kidney Disease (CKD)
- Hyperkalemia (HK)

## Interventions

- **DRUG:** Patiromer
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01810939
- **Lead sponsor:** Relypsa, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01810939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01810939, "A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01810939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*